ALCAM and neoplasm: Finally, only one study in stage II CRC patients reported that CD166 expression may become a predictive biomarker of OS and disease-specific survival using multivariate logistic regression analysis [23], which suggests that additional studies with large populations are needed to confirm the predictive role of CD166 expression in CRC patients with the detailed tumor staging.